Following this activity, participants should be able to: (1) Identify the potential for immune checkpoint inhibitor (ICI) therapy to cause uncommon immune-related adverse events (irAEs) including oral toxicities, which require prompt management in patients with cancer. (2) Recognize the types and grading of oral irAEs which may affect the mucosal tissue and salivary glands. (3) Develop proactive strategies for the supportive care, management, and monitoring of patients with oral irAEs.
- Provider:National Comprehensive Cancer Network
- Activity Link: https://education.nccn.org/node/95587
- Start Date: 2024-06-13 05:00:00
- End Date: 2024-06-13 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: Exelixis - Amount: 0.0 - Is Kind Support: False Source: GlaxoSmithKline - Amount: 0.0 - Is Kind Support: False Source: Menarini-Stemline - Amount: 0.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 0.0 - Is Kind Support: False Source: Regeneron Pharmaceuticals, Inc. - Amount: 0.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest